• Baked In
  • Posts
  • 💸 Trulieve Just Crashed the Russell 2000 — Index Funds Have to Buy

💸 Trulieve Just Crashed the Russell 2000 — Index Funds Have to Buy

Good morning, loyal readers —

Trulieve has cleared a threshold that few U.S. cannabis operators have even approached, landing on FTSE Russell’s preliminary addition list for the Russell 2000 and Russell 3000 effective after the close on December 11. The inclusion does more than expand visibility — it places the company in front of a vast pool of index-tracking capital that must own the stock at its weight, steadily broadening the shareholder base beyond the specialists who have long dominated the sector. For a business that only recently uplisted to the NYSE, the move marks a structural shift toward deeper liquidity and a more generalist investor audience.

Scroll down for our full analysis…

Own Your Edge. TDR subscribers that are new customers get 15% off: https://frepouch.com/discount/DALES

💸 The Tape

Trulieve announced Monday that FTSE Russell has placed it on the preliminary addition list for the Russell 2000 and Russell 3000, with membership taking effect after the close on December 11, 2026. Kim Rivers kept the statement to two sentences, the second of which is the one that matters: “Index inclusion raises awareness of Trulieve, ultimately leading to greater liquidity.” That’s accurate, and it understates the mechanism.

What actually happened

FTSE Russell moved to a semi-annual reconstitution cycle this year, adding a November refresh to the traditional June rebalance. Trulieve uplisted to the NYSE in June, after the annual reconstitution’s rank day had passed, which meant it missed the 2026 June cycle entirely. The November window is the first time the stock was eligible, and it cleared the bar: a U.S.-domiciled company, listed on a national exchange, with a market capitalization inside the top 3,000 U.S. equities by total market value. That’s it. The Russell has no profitability screen, no sector exclusion, and no discretion. If you meet the rank-day criteria, you’re in.

This is the third index milestone of the year. Trulieve was already added to the S&P Total Market, S&P Completion and Morningstar Total Stock Market indices after the NYSE listing. Those are broad benchmarks with meaningful but diffuse passive ownership. The Russell 2000 is different in kind.

Why the Russell 2000 is different

The Russell 2000 is the dominant small-cap benchmark in U.S. equity markets. FTSE Russell puts the assets benchmarked to or invested in products tracking its U.S. indexes at roughly $12 trillion. The iShares Russell 2000 ETF alone holds on the order of $70 billion. Vanguard, State Street and dozens of institutional index mandates add to it. Industry estimates commonly put passive ownership of a typical Russell 2000 constituent somewhere in the high single digits to low teens as a percentage of float, and that doesn’t count the active small-cap managers who are benchmarked to the index and will now have a tracking-error reason to own the name or justify not owning it.

For Trulieve, that translates into a wall of forced buying on or around December 11. Index funds don’t choose; they replicate. Every dollar tracking the Russell 2000 must own Trulieve at its index weight by the close that Friday, and the stock will show up in the quarterly rebalance of every small-cap value, growth and dividend-tilted product built off the Russell framework from that point forward.

The liquidity change

Here is where the game changes for a company that spent six years on the CSE and OTC. Trulieve’s trading volume since the NYSE listing has been respectable but thin for a company of its revenue scale, and the shareholder base is still skewed toward the retail investors and cannabis specialists who held it through the OTC years. Index inclusion does three things to that picture.

First, it installs a permanent passive bid. Index funds are holders, not traders. Once they own the position, they adjust only at rebalances and on flows, which removes a block of shares from the daily float and tightens the supply of stock available to sell.

Second, it brings in the benchmarked active managers. Small-cap funds that have ignored cannabis because it wasn’t in their universe now have Trulieve in their benchmark. Some will buy. Many will at least run the numbers. Trulieve’s Q3 print, a 64% gross margin, 39% adjusted EBITDA margin, $327 million in cash and $240 million of annualized free cash flow, is the kind of profile that screens well against the Russell 2000’s median constituent, which is unprofitable.

Third, it changes who sets the price. A stock dominated by sector specialists trades on sector news: DEA filings, state ballot measures, 280E headlines. A stock owned by generalist small-cap funds trades on earnings, margins and multiples relative to peers in the index. That shift is what Rivers means by awareness, and it’s the reason Trulieve restructured, domesticated and uplisted in the first place.

Next steps and what to expect

The preliminary list was published November 13. FTSE Russell will issue updates on November 20 and 27 and December 4, and the final list is locked at the close on December 11. Trulieve’s inclusion is not in doubt unless the company fails a listing or domicile test, which it won’t.

Expect elevated volume into the December 11 close, when index funds execute their adds. Reconstitution-day volume for a new Russell 2000 entrant commonly runs several multiples of the average daily figure. Expect arbitrage ahead of it: event-driven funds buy anticipated adds in the weeks before and sell into the passive demand on the day, which can lift the stock into inclusion and then flatten it afterward. The pattern is well documented and should not be mistaken for a fundamental signal in either direction.

After December, watch for three things. Options liquidity, which tends to deepen once market makers have index-fund flow to hedge against. Analyst initiations from generalist small-cap desks that cover the Russell universe rather than the cannabis sector. And the next reconstitution in June 2027, when Trulieve’s rank will determine whether it stays in the 2000 or, if the market cap grows enough, migrates toward the Russell 1000.

The structural point

Trulieve’s deconsolidation of Harvest shrank reported revenue 20% and got it an NYSE ticker. That ticker got it into the S&P Total Market, the Morningstar TMI and now the Russell 2000, each of which brings a mandatory buyer that doesn’t care whether cannabis is in Schedule I or III. No other U.S. cannabis operator has done this. Green Thumb, Curaleaf and Verano still trade on Canadian exchanges and OTC markets that no U.S. index touches. Until they find their own path to a U.S. listing, they are competing for the same specialist capital they always have, while Trulieve competes for the $12 trillion that doesn’t know what 280E is.

The game-changer isn’t the headline. It’s that from December 11 onward, Trulieve has a shareholder base that was told to buy it. #Position

📈 Dog Walkers

$LEEEF ( ▲ 1.93% ) Partners With Headwaters

LEEF Brands announced a strategic partnership with Headwaters, the Northern California cultivator and distributor run by Tristan Strauss, to move LEEF’s Salisbury Canyon Ranch output into the flower market for the first time. LEEF will grow flower using Headwaters’ genetics and cultivation expertise, Headwaters will sell it through its wholesale network, and LEEF’s concentrates get added to Headwaters’ portfolio in return. The arrangement starts this month, with expanded cultivation and commercial activity planned for 2027.

The reason is in one line of the release: California’s distillate market is experiencing pricing compression. LEEF built its business on being the state’s largest concentrate manufacturer, buying or growing biomass and converting it into distillate for the vape and edible supply chain. That model works when distillate prices hold. They haven’t. Oversupply from Croptober harvests, falling vape cart prices and a shrinking licensed retail base have pushed distillate toward commodity economics, and LEEF’s 1,900-acre Salisbury Canyon footprint was producing more biomass than the distillate market could absorb profitably.

Flower is the obvious alternative, and the smart part is that LEEF didn’t try to do it alone. Growing commodity biomass for extraction and growing sellable flower are different disciplines, and the second requires genetics, trim, cure and a buyer base that LEEF has never built. Headwaters has all three. Micah Anderson’s framing, “flower represents a significant opportunity for us,” is really an admission that the distillate-only strategy needed a hedge.

What’s missing is everything an investor would want to size it: no acreage committed, no volume targets, no revenue split, no indication of whether this is a license, a JV or a handshake. Both sides have reasons to keep it loose while they see how the first crop sells.

Still, for a company that just added a policy strategist to its board and filed DEA registration applications across California and Nevada, diversifying away from a collapsing commodity price is the right move at the right time. The question is whether California flower, at $334 a pound outdoor, is a better business than the one it’s leaving.


🗞️ The News

📺 Trade To Black

MariMed's Record Quarter and Bold New York Plan | Trade to Black

  • MariMed CEO Jon Levine and CCO Ryan Crandall join after a record quarter: revenue up 8.5% to $44.2M, adjusted EBITDA up 18% sequentially to $4.7M, and $10.4M in cash, the company’s strongest position in two years. Branded products now sit in 721 stores, up 13%.

  • New York is the next big swing: Crandall calls it the largest state opportunity MariMed has seen, entering through wholesale and licensing with no retail footprint and the potential to nearly double its door count. Maine is already working, with Betty’s Eddies the #2 edible in the state.

  • Consolidation talk: Levine says MariMed is “always listening” but won’t sell for the wrong number, and would welcome the right merger partner. The hosts press on the balance sheet debt, the planned reverse split and a possible U.S. exchange listing.

  • The loyalty program is Crandall’s major focus heading into 2027, and the conversation closes on what changes if rescheduling or banking reform finally lands, and how federal hemp restrictions ripple through MariMed’s markets.